CNS Pharmaceuticals, Inc.
CNSP
NASDAQ·Healthcare·Biotechnology·Mkt cap $8.4M
$5.24
▼ -1.13%
P/E
—
Mkt Cap
$8.4M
52-Wk Range
$1.90–$10.59
52-Week Range
$1.90 - $10.59
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 40.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary anthracycline drug candidate with focused CNS tumor indication
- Strategic partnerships with leading research institutions and pharmaceutical companies
- Specialized expertise in brain tumor and central nervous system oncology
- Clinical development pipeline with potential first-mover advantage in glioblastoma treatment
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Advancement of Berubicin through clinical trial phases toward FDA approval
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+6.9% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CNSP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 18, 2026
AUG 12, 2026
Reported EPS of -$0.38 vs -$0.24 consensus (-58.3% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-58.3%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CNSP stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related